NewMedical Technology Will Donate a Portion of All Sales to the Melanoma Research Foundation to Support Skin Cancer Awareness Month

April 30, 2014

Throughout the month of May, NewMedical Technology, Inc. will donate a portion of all sales from NewGel+ and NewGel+E products to the Melanoma Research Foundation to assist in research, advocacy and help in the fight against melanoma.

Northbrook, IL (PRWEB) April 30, 2014

Melanoma is a type of cancer, most often of the skin. It occurs in melanocytes, the cells that color the skin and form moles.

  •     Melanoma is the most serious type of skin cancer because it can spread to lymph nodes and distant organs.
  •     In 2014, it is expected that approximately 77,000 Americans will be diagnosed with melanoma, resulting in nearly 10,000 deaths.

“We are proud to partner with the Melanoma Research Foundation. The MRF is committed to research, education, and advocacy in the battle to find more effective treatments and, ultimately, a cure for melanoma,” said Mike Hanna, CEO, NewMedical Technology, Inc. “With our support, we hope to help raise awareness and support medical research to find effective new treatments for melanoma. Many of our partner dermatologists and plastic surgeons refer their patients to our products after melanoma surgery. We see the increasing prevalence of this life-threatening cancer, and want to contribute to this worthwhile cause.”

About NewMedical Technology

NewMedical Technology is a global healthcare company that develops and manufactures innovative solutions for scar management and skin care. Their current core products are NewGel+ and NewGel+E; a silicone gel sheeting and silicone gel used in scar management and scar prevention. Developed by doctors for use in hospitals and clinics, the NEWGEL+ line of scar management products are the gold standard for treating scars following Mohs surgery to remove skin cancer, as well as scars resulting from all other surgeries, burns, and traumatic injuries.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/04/prweb11789690.htm

Source: prweb

comments powered by Disqus